Inventor · disambiguated record
James N. Kochenderfer
Also filed as: KOCHENDERFER JAMES N · KOCHENDERFER JAMES NOBLE
29 granted patents·6 pending applications·412 citations·filing 2013–2025
97Inventor score
Files withUS HEALTH27KITE PHARMA INC6THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES1THE UNITED STATES OF AMERICAAS REPRESENTED BY THE SECRETARYDEPARTMENT OF HEALTH AND HUMAN SERVICES1
Top patents by PatentIndex Score
35 records- 0199US9765342B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2013·Granted Sep 19, 2017·127 cites·19 claims
- 0298US11377660B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2020·Granted Jul 5, 2022·7 cites·29 claims
- 0398US11359204B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2020·Granted Jun 14, 2022·7 cites·28 claims
- 0498US10287350B2Chimeric antigen receptors targeting CD-19US HEALTH·Filed 2015·Granted May 14, 2019·39 cites·18 claims
- 0597US11827889B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2022·Granted Nov 28, 2023·4 cites·18 claims
- 0697US11066674B2Chimeric antigen receptors targeting b-cell maturation antigenUS HEALTH·Filed 2020·Granted Jul 20, 2021·6 cites·30 claims
- 0797US10900042B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Jan 26, 2021·8 cites·24 claims
- 0897US10876123B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Dec 29, 2020·8 cites·28 claims
- 0997US10844387B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Nov 24, 2020·8 cites·25 claims
- 1097US10815487B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Oct 27, 2020·8 cites·28 claims
- 1197US10815488B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Oct 27, 2020·8 cites·19 claims
- 1297US10767184B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2017·Granted Sep 8, 2020·11 cites·59 claims
- 1396US10837019B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Nov 17, 2020·7 cites·25 claims
- 1496US10829768B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Nov 10, 2020·7 cites·25 claims
- 1596US10829769B2Chimeric antigen receptors targeting b-cell maturation antigenUS HEALTH·Filed 2019·Granted Nov 10, 2020·7 cites·27 claims
- 1696US10829767B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2019·Granted Nov 10, 2020·7 cites·27 claims
- 1795US11773396B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2022·Granted Oct 3, 2023·1 cites·15 claims
- 1895US10815301B2Anti-CD30 chimeric antigen receptorsUS HEALTH·Filed 2016·Granted Oct 27, 2020·15 cites·21 claims
- 1995US10738313B2Chimeric antigen receptors targeting B-cell maturation antigenTHE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2019·Granted Aug 11, 2020·7 cites·19 claims
- 2095US10322146B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2017·Granted Jun 18, 2019·17 cites·30 claims
- 2195US9855298B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2016·Granted Jan 2, 2018·80 cites·30 claims
- 2294US12180484B2Chimeric antigen receptors targeting B-cell maturation antigenUS HEALTH·Filed 2022·Granted Dec 31, 2024·1 cites·20 claims
- 2393US11236161B2Chimeric antigen receptors targeting CD-19US HEALTH·Filed 2019·Granted Feb 1, 2022·4 cites·20 claims
- 2493US10738312B2Chimeric antigen receptors targeting B-cell maturation antigenTHE UNITED STATES OF AMERICAAS REPRESENTED BY THE SECRETARYDEPARTMENT OF HEALTH AND HUMAN SERVICES·Filed 2019·Granted Aug 11, 2020·7 cites·19 claims
- 2593US2025136998A1Chimeric antigen receptors targeting b-cell maturation antigenUS HEALTH·Filed 2024·Application pending·0 cites
- 2689US11951131B2Anti-SLAMF7 chimeric antigen receptorsUS HEALTH·Filed 2019·Granted Apr 9, 2024·4 cites·16 claims
- 2789US11779601B2Diagnostic methods for T cell therapyKITE PHARMA INC·Filed 2016·Granted Oct 10, 2023·5 cites·13 claims
- 2887US11491187B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2018·Granted Nov 8, 2022·2 cites·15 claims
- 2985US2025367221A1Methods of conditioning patients for t cell therapyKITE PHARMA INC·Filed 2025·Application pending·0 cites
- 3081US12458654B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2022·Granted Nov 4, 2025·0 cites·12 claims
- 3180US12473359B2Chimeric antigen receptors targeting CD-19US HEALTH·Filed 2022·Granted Nov 18, 2025·0 cites·44 claims
- 3275US2022153838A1Chimeric antigen receptors targeting cd-19US HEALTH·Filed 2021·Application pending·0 cites
- 3351US2024165153A1Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereofUS HEALTH·Filed 2022·Application pending·0 cites
- 3450US2020138865A1Anti-b-cell maturation antigen chimeric antigen receptors with human domainsUS HEALTH·Filed 2018·Application pending·0 cites
- 3546US2021363245A1Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their usesUS HEALTH·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James N. Kochenderfer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →